Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
The DOI matches its Crossref record; 3,518 of the 3,518 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Antidepressants for cocaine dependence
Silva de Lima, M., Farrell, M., Lima Reisser, A. A., & Soares, B. (2003) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002950 · Cited by 78
RetractedGlycosyl Modification Facilitates Homo- and Hetero-oligomerization of the Serotonin Transporter
Ozaslan, D., Wang, S., Ahmed, B. A., Kocabas, A. M., McCastlain, J. C., Bene, A., & Kilic, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306360200 · Cited by 53
RetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Emergence of Scaling in Random Networks
Barabási, A.-L., & Albert, R. (1999) · Science · doi:10.1126/science.286.5439.509 · Cited by 36,135
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Classification and Regression Trees.
Ryzin, J. V., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1986) · Journal of the American Statistical Association · doi:10.2307/2288003 · Cited by 20,825
Hierarchical Grouping to Optimize an Objective Function
Ward, J. H. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500845 · Cited by 20,598
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Self-citationMulti-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Self-citationWang, J.-W., David, D. J., Monckton, J. E., Battaglia, F., & Hen, R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3632-07.2008 · Cited by 550
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Self-citationANISMAN, H., MERALI, Z., & HAYLEY, S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 337
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions
MILLAN, M., MARIN, P., BOCKAERT, J., & MANNOURYLACOUR, C. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.007 · Cited by 320
Self-citationDuric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304
“The potential role of 5-HT receptors is supported by the monoamine theory of MDD, most notably the therapeutic effectiveness of SSRIs (Coppen & Doogan, 1988 ; Millan, 2006).”
Godbout, J. P., Moreau, M., Lestage, J., Chen, J., Sparkman, N. L., Connor, J. O., Castanon, N., Kelley, K. W., Dantzer, R., & Johnson, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301649 · Cited by 299
Anisman, H. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0902 · Cited by 292
“Major depressive disorder has been associated with variations of levels and turnover of serotonin (5-HT), alterations of the 5-HT transporter and several 5-HT receptors (5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C) and dopamine and norepinephrine function.(2,3) Moreover, depression has been associated with alterations of peptid…”
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Neuroinflammation in Bipolar Depression
Benedetti, F., Aggio, V., Pratesi, M. L., Greco, G., & Furlan, R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00071 · Cited by 274
Serotonin, inhibition, and negative mood
Dayan, P., & Huys, Q. J. M. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0040004 · Cited by 263
“Furthermore, while SSRIs are used in the treatment of depression, genetically induced, constitutive decreases in the efficiency of 5-HT reuptake are a risk factor for depression [22–24].”
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
“Several observations support the idea that compounds working through multitarget mechanisms will have a superior effect on both cardinal and comorbid symptoms of depression compared with selective compounds (for review, see Millan, 2006).”
BackgroundBarnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
The role of serotonin receptor subtypes in treating depression: a review of animal studies
Carr, G. V., & Lucki, I. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2097-z · Cited by 260
Gut microbiota–brain axis in depression: the role of neuroinflammation
Carlessi, A. S., Borba, L. A., Zugno, A. I., Quevedo, J., & Réus, G. Z. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14631 · Cited by 243
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Self-citationRéus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
Important messages in the ‘post’: recent discoveries in 5-HT neurone feedback control
Sharp, T., Boothman, L., Raley, J., & Quérée, P. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.009 · Cited by 190
Chanrion, B., Mannoury la Cour, C., Bertaso, F., Lerner-Natoli, M., Freissmuth, M., Millan, M. J., Bockaert, J., & Marin, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610964104 · Cited by 180
Self-citationO’Leary, O. F., Bechtholt, A. J., Crowley, J. J., Hill, T. E., Page, M. E., & Lucki, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0728-9 · Cited by 177
“When administered chronically, antidepressants produce changes in receptor regulation, cell signaling, or neuroplasticity, in part, due to persistent overexposure to monoamine neurotransmitters, and these changes may also contribute to their therapeutic effects (Caldecott-Hazard and Schneider 1992; Millan 2006).”
BackgroundA critical review of human endotoxin administration as an experimental paradigm of depression.
DellaGioia, N., & Hannestad, J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.014 · Cited by 175
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Self-citationBenedetti, F., Riccaboni, R., Locatelli, C., Poletti, S., Dallaspezia, S., & Colombo, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08455 · Cited by 116
Zhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
“provide therapeutic benefits by affecting more than one neurotransmitter system and thereby via different points of intervention modulate downstream events that are needed for the antidepressant activity (Millan 2006; Wong et al. 2008).”
Circadian Rhythms, Melatonin and Depression
A. Quera Salva, M., Hartley, S., Barbot, F., C. Alvarez, J., Lofaso, F., & Guilleminault, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796197188 · Cited by 100
Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine
Johnson, K. W., Shameer, K., Glicksberg, B. S., Readhead, B., Sengupta, P. P., Björkegren, J. L. M., Kovacic, J. C., & Dudley, J. T. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.11.010 · Cited by 83
El Iskandrani, K. S., Oosterhof, C. A., El Mansari, M., & Blier, P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573809 · Cited by 75
“These effects could be a consequence of a direct effect of ketamine on NE and DA neurons, or indirectly due to an effect of ketamine on their glutamatergic afferents which have previously been shown to control monoaminergic neuron firing (Carlsson et al., 2001; Millan, 2006; Paul and Skolnick, 2003).”
BackgroundHigher Baseline Interleukin-1β and TNF-α Hamper Antidepressant Response in Major Depressive Disorder
Benedetti, F., Poletti, S., Vai, B., Mazza, M. G., Lorenzi, C., Brioschi, S., Aggio, V., Branchi, I., Colombo, C., Furlan, R., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.009 · Cited by 62
Hisaoka, K., Tsuchioka, M., Yano, R., Maeda, N., Kajitani, N., Morioka, N., Nakata, Y., & Takebayashi, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.224683 · Cited by 57
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Haegen, M. V., & Luminet, O. (2015) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2015.1067279 · Cited by 32
“In vivo and postmortem investigations suggest that frontal-striatal-thalamic and limbic-thalamic-frontal networks are implied in the pathogenesis of depression disorder and especially a disruption of limbic dopaminergic signaling system, which plays a pivotal role in the regulation of mood and emotion, cognition, and…”
BackgroundMolecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity
Smith, D. F., & Jakobsen, S. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00008 · Cited by 25
Suzuki, M., Dallaspezia, S., Locatelli, C., Uchiyama, M., Colombo, C., & Benedetti, F. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.066 · Cited by 22
Yuan, X., Chai, J., Xu, W., & Zhao, Y. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10326-z · Cited by 15
Metadata
- Authors
- Millan, M. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 110
- Issue
- 2
- Pages
- 135-370
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2073570537
- Cited by
- 551
- References
- 3,518
- FWCI
- 21.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.